The European Medicines Agency’s (EMA) Committee has accepted Aurobindo Pharma subsidiary CuraTeQ Biologics' request to withdraw the applications for marketing authorization of ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar).
